Novum Pharmaceutical Research Services, a subsidiary of Lambda Therapeutic Research, is a CRO with over 50 years of experience in the industry. Lambda & Novum deliver comprehensive, end-to-end clinical research services to the innovator, biotech, and generic pharmaceutical industries worldwide.
Lambda’s commitment to excellence has garnered significant recognition, including the ‘Best Indian CRO’ award from Frost & Sullivan (USA) and the ‘Great Indian Workplace’ title from UBS Transformance. Recent accolades include the ‘Regulatory Excellence’ Award at the CPhI Pharma Awards 2023 and the ‘Industry Partner of the Year’ Award at the Global Generics & Biosimilar Awards 2023. With a focus on secure IT infrastructure and automation, we ensure timely project delivery and strict adherence to global regulatory standards. Our exemplary regulatory track record includes over 60 successful international inspections and audits by esteemed authorities such as the USFDA, EMEA, MHRA, EU member states, and other global bodies over the past five years.
We look forward to showcasing how our extensive experience and expertise in drug development can drive your project’s success. Take the opportunity to meet our representative – Ms. Cathy Lopez (Vice President, Business Development) and discuss how we can customize our full-service capabilities to meet your specific needs.
Meet us at AAD Annual Meeting 2025
Novum Pharmaceutical Research Services and Lambda Therapeutic Research are excited to announce their participation in 2025 AAD Annual Meeting, at Orlando, FL, which will take place from 7 to 11 March 2025. Experience the Lambda & Novum Advantage in Dermatology Clinical Trials, backed by extensive expertise across diverse indications.
Schedule a meeting by filling out the form or reach out at to discuss how Lambda and Novum can support your drug development projects.